Cobicistat

證據等級: L5

預測適應症: 3 個

COBICISTAT: From HIV-1 Treatment (Pharmacokinetic Booster) to Simian Immunodeficiency Virus Infection

One-Sentence Summary

Cobicistat is a selective CYP3A inhibitor used as a pharmacokinetic (PK) booster within combination antiretroviral regimens for HIV-1 infection — it has no intrinsic antiviral activity of its own. The TxGNN model predicts it may be effective for Simian Immunodeficiency Virus (SIV) Infection, with 0 clinical trials and 0 publications currently supporting this direction. This high-scoring prediction appears to reflect graph-based proximity between HIV-1 and SIV in the knowledge graph rather than any direct pharmacological evidence.

Quick Overview

Item	Content
Original Indication	HIV-1 infection (as a PK booster in combination antiretroviral therapy)
Predicted New Indication	Simian Immunodeficiency Virus (SIV) Infection
TxGNN Prediction Score	99.92%
Evidence Level	L5
Canada Market Status	Not marketed
Number of DINs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on established pharmacological knowledge, cobicistat is a mechanism-based, selective inhibitor of CYP3A4 and CYP3A5. It does not possess intrinsic antiviral activity; rather, it functions purely as a pharmacokinetic enhancer — slowing the hepatic and intestinal metabolism of co-administered antiretroviral drugs (such as protease inhibitors and integrase strand transfer inhibitors) to increase their plasma exposure. It is approved as a component of fixed-dose combinations including elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild, Genvoya) and darunavir/cobicistat (Prezcobix, Symtuza).

Simian Immunodeficiency Virus (SIV) is a lentivirus infecting non-human primates and is evolutionarily closely related to HIV-1, sharing the same viral family (Retroviridae: Lentivirus), CD4+ T cell tropism, and reverse transcriptase-dependent replication pathway. In the TxGNN knowledge graph, SIV and HIV-1 therefore share multiple high-weight neighboring nodes, which likely explains why the model assigns cobicistat a high prediction score for SIV — the graph proximity algorithm propagates cobicistat’s HIV-1 association directly to SIV through these shared nodes.

However, this mechanistic link is indirect and structurally weak. Cobicistat’s entire therapeutic rationale rests on human hepatic CYP3A pharmacokinetics; whether CYP3A inhibition provides analogous PK boosting in non-human primate species — whose CYP enzyme profiles differ meaningfully from humans — has not been established. Furthermore, SIV infection is a veterinary and preclinical animal-model disease, not a human clinical target, making direct clinical translation uncertain at best.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

Cobicistat is not currently marketed in Canada as a standalone product (0 DINs on record). No Health Canada drug identification numbers are registered for cobicistat in this dataset. Note that cobicistat-containing fixed-dose combination products (e.g., Stribild, Genvoya, Prezcobix) may hold separate DINs under their combination brand names, which are not captured here.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a high TxGNN score (99.92%), this prediction is an artefact of graph-based proximity between HIV-1 and SIV rather than a genuine pharmacological signal — cobicistat has no antiviral activity, SIV is an animal disease rather than a human clinical indication, and there is zero supporting clinical or literature evidence.

To proceed, the following is needed:

Mechanistic clarification: Determine whether any SIV-active antiviral agents are CYP3A substrates that could plausibly benefit from cobicistat-mediated PK boosting in non-human primates
Non-human primate PK data: Assess whether CYP3A inhibition by cobicistat translates to meaningful exposure enhancement in macaque or other relevant species
MOA data retrieval: Obtain full DrugBank MOA record (currently unavailable) to enable complete mechanism-based evaluation
Regulatory pathway assessment: Cobicistat is not marketed in Canada; any standalone regulatory submission pathway would need to be scoped before clinical application could be considered
Reconsideration of indication target: Given cobicistat’s role as a booster, repurposing evaluation should focus on human diseases where CYP3A substrate drugs are underexposed, rather than novel disease indications driven solely by graph proximity
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.